Incyclix Bio is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers
Incyclix Bio is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development.